GI Side Effects Anesthesia Risks With GLP-1 Agonists What to Know

The Surgical Risk Nobody Told You About

Medscape is one of the most trusted medical information sources for healthcare professionals, so when they publish a video specifically addressing anesthesia risks with GLP-1 medications, it carries weight. This is not social media speculation or influencer concern trolling. This is the medical establishment formally alerting clinicians (and, by extension, patients) to a real safety consideration that has changed pre-surgical protocols across the country.

The core issue is straightforward: GLP-1 receptor agonists slow gastric emptying. This means food stays in your stomach longer than normal. When you undergo general anesthesia, there is a risk that stomach contents can travel up the esophagus and enter the lungs (aspiration). Aspiration pneumonia is a serious, potentially life-threatening complication. Standard pre-surgical fasting protocols (nothing to eat for 8 hours, nothing to drink for 2 hours before surgery) were designed for patients with normal gastric emptying. Those protocols may not be sufficient for patients on GLP-1 medications.

Why Standard Fasting Guidelines Fall Short

The Medscape video explains the gastric emptying data that prompted the American Society of Anesthesiologists (ASA) to update their guidance. In patients not taking GLP-1 medications, an 8-hour fast typically results in a nearly empty stomach. But studies using ultrasound and other imaging to assess gastric contents in GLP-1 patients have found significant residual food and liquid in the stomach even after extended fasting periods.

The degree of gastric emptying delay varies between patients and between medications. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have long half-lives, meaning their effects on gastric motility persist for days after the last dose. Simply skipping a dose the day before surgery may not be enough to normalize gastric emptying. The drug is still active in your system, still slowing your digestion, even if you did not take it yesterday.

This is different from shorter-acting medications that clear the system quickly. The extended action that makes weekly GLP-1 injections convenient for treatment purposes is the same property that creates this surgical challenge. You canmore than stop the medication and expect its effects to disappear overnight.

Current Guidelines for Pre-Surgical Management

The video reviews the updated ASA recommendations, which represent the current standard of care. For patients on daily GLP-1 medications (like liraglutide or oral semaglutide), the recommendation is to hold the medication on the day of surgery and the day before. For patients on weekly GLP-1 injections (like semaglutide or tirzepatide), the recommendation is more aggressive: hold the medication for at least one week before elective surgery.

Even with medication held, the ASA recommends that anesthesiologists treat GLP-1 patients as having a potentially full stomach. This means using rapid sequence intubation (a technique that secures the airway quickly to minimize aspiration risk), considering a gastric ultrasound to assess stomach contents before induction, and having suction equipment immediately available.

For emergency surgeries where holding the medication in advance is not possible, the ASA recommends a full-stomach precaution approach regardless of fasting duration. The assumption is that the patient may have residual gastric contents and the anesthesia team should plan accordingly.

The GI Side Effects That Compound the Risk

The Medscape video does not limit its discussion to anesthesia. It also covers the gastrointestinal side effects of GLP-1 medications that form the backdrop for the surgical concern. Nausea affects 20-44% of patients in clinical trials. Vomiting affects 5-25%. Constipation affects 10-24%. Diarrhea affects 5-20%. These percentages represent clinical trial populations with careful dose titration; real-world rates may vary.

The GI side effects are dose-dependent and typically most pronounced during dose escalation. Starting at a low dose and increasing gradually (as recommended in prescribing information) allows the gut to adapt and reduces the severity and duration of symptoms. Patients who jump to higher doses too quickly, or who restart at their previous dose after a break in treatment, tend to experience more severe GI symptoms.

For surgical purposes, the concern is more than the chronic slowing of gastric emptying but the potential for acute GI distress (nausea, vomiting) during the peri-operative period. Anesthesia itself can cause nausea, and GLP-1 medications that amplify this tendency create a higher-risk scenario for post-operative vomiting and aspiration during recovery.

Endoscopy and Other Procedures

The video also addresses a question that many GLP-1 patients face: what about endoscopy? Upper endoscopy and colonoscopy both require gastric or bowel preparation, and GLP-1-related motility changes can affect the quality of preparation and the safety of the procedure.

For upper endoscopy, the same aspiration concerns apply as with general anesthesia. A stomach that is not fully empty poses a risk during sedation. Some gastroenterologists now require extended fasting periods or a liquid-only diet for a longer period before upper endoscopy in GLP-1 patients.

For colonoscopy, the concern is slightly different. Adequate bowel preparation requires the prep solution to move through the entire GI tract effectively. Slowed motility from GLP-1 medications can result in incomplete bowel preparation, which leads to poor visualization during the procedure and may necessitate a repeat colonoscopy. Some gastroenterologists recommend a modified prep protocol for GLP-1 patients, starting the preparation earlier or using a higher-volume prep solution.

What Patients Should Do

The practical takeaway from this Medscape video is clear: if you are on a GLP-1 medication and have any surgical procedure or endoscopic procedure scheduled, communicate this to every member of your medical team. Tell your surgeon. Tell your anesthesiologist. Tell your gastroenterologist. Tell the pre-operative nurse. Do not assume that your medication list will be automatically reviewed with this specific concern in mind.

Ask your prescribing physician about when to hold your GLP-1 medication before your procedure. For weekly injections, this usually means timing your last injection so that surgery falls at least 7 days after the dose. For daily medications, holding for 1-2 days before surgery is typical. Follow whatever extended fasting instructions your anesthesiologist provides, even if they are longer than what you experienced for previous surgeries before you started GLP-1 therapy.

On the day of the procedure, honestly report what you have eaten and when. If you ate or drank something within the fasting window (even a small amount), tell your anesthesia team. They would rather delay a procedure than manage an aspiration event. This is not an area where minimizing or forgetting to mention details is harmless.

The Broader Lesson About Medication Communication

This video highlights a broader challenge in modern medicine: patients are often on medications prescribed by one specialist that affect the care provided by a different specialist. Your endocrinologist or obesity medicine doctor prescribes your GLP-1 medication. Your surgeon plans your operation. Your anesthesiologist manages your airway. Unless all of these providers are aware of and accounting for your full medication picture, important safety considerations can fall through the cracks.

As a patient, you are the common thread connecting all of these providers. You are the person who knows what medications you take, when you take them, and what effects you experience. Carrying an updated medication list to every medical appointment, including the dose, frequency, and prescribing physician for each medication, is one of the simplest and most effective safety practices you can adopt.

Looking Forward

As GLP-1 prescriptions continue to grow, anesthesia and surgical protocols will continue to evolve. Research is ongoing to better quantify the gastric emptying delay associated with different GLP-1 medications at different doses, which will allow for more precise pre-surgical guidance. Point-of-care gastric ultrasound, which can assess stomach contents in real time at the bedside, is becoming more widely adopted and may eventually replace blanket fasting rules with individualized assessment.

For now, the standard of care is conservative: hold the medication, fast longer, and assume the stomach may not be empty. These precautions add some inconvenience to the surgical experience but dramatically reduce a real and preventable risk. If you are on a GLP-1 medication and facing any procedure that involves sedation or anesthesia, this Medscape video gives you the knowledge to advocate for your own safety.

Special Populations and Additional Considerations

The video touches on several special populations deserving additional consideration. Elderly patients on GLP-1 medications may have naturally slower gastric emptying due to age-related gut motility changes. The additive effect of medication-induced and age-related slowing could create higher baseline aspiration risk, making pre-surgical GLP-1 management even more critical in older patients.

Patients with diabetes on GLP-1 therapy present unique pre-surgical challenges because holding the medication before surgery can cause blood sugar to rise, sometimes dramatically. The surgical team and endocrinologist need to coordinate glucose management during the medication-free period, which may involve temporary insulin coverage, more frequent monitoring, or adjustments to other diabetes medications during the perioperative window.

Pregnant patients who should discontinue GLP-1 therapy before pregnancy may have residual gastric slowing after stopping, depending on recency of discontinuation. If obstetric procedures requiring anesthesia become necessary during this transition period, the anesthesia team should know about recent GLP-1 exposure and plan accordingly.

Dental procedures under sedation also warrant GLP-1 awareness. While dental sedation is typically lighter than general anesthesia, it still carries aspiration risk in patients with residual stomach contents. If you are undergoing dental surgery with sedation (wisdom tooth extraction, implant placement), inform your oral surgeon about your GLP-1 medication and follow any modified fasting instructions they provide.

The takeaway from this Medscape video is fundamentally about communication. GLP-1 medications change how your digestive system functions, and those changes have implications for any medical procedure involving sedation or anesthesia. You are the person who knows what medications you take. Making sure every member of your care team has that information, and understanding why it matters for your safety, is one of the simplest and most important things you can do as a patient navigating the modern healthcare system while on GLP-1 therapy.